CD274 and neoplasm: Research demonstrates that PD-L1 translocates to cell nuclei where it modulates inflammatory and immune responses, promotes tumor invasiveness and metastasis, and triggers expression of immune checkpoint molecules unaffected by PD-1/PD-L1 blockade, resulting in acquired resistance to immunotherapy [137,139].